**5. Conclusions**

In conclusion, our results have demonstrated an acceptable safety profile of (1→3)-β-glucantargeting <sup>213</sup>Bi-400-2 antibody in dogs. RIT may be a useful adjunct therapy for invasive fungal infections and have a role to play in speeding resolution of an infection by helping the body to reduce the infectious load to a lower level where either the immune system or other therapies may be more effective. The clinical trial will recruit canine patients with invasive fungal infections and will also provide the information needed for clinical translation into human patients with IFI.

**Author Contributions:** Conceptualization, E.D. and E.S.; methodology, E.D., E.S., and H.B.; software, M.H. (Matthew Hutcheson); validation, E.D. and E.S.; formal analysis, M.H. (Muath Helal) and H.B.; investigation, M.H. (Muath Helal), K.J.H.A., M.E.M., R.J., and M.H. (Matthew Hutcheson); resources, E.D. and E.S.; data curation, E.D. and E.S.; writing—original draft preparation, M.H. (Muath Helal); writing—review and editing, E.D., E.S., and H.B.; visualization, M.H. (Muath Helal); supervision, E.D. and E.S.; project administration, E.D.; funding acquisition, E.D. and E.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Saskatchewan Health Research Foundation, grant number 4172.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
